Collegium Pharmaceutical Receives $22,500,000 New Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f419bf02-c8ca-4a43-a3a8-f5bf2ee5cf21&Preview=1 - Date
2/22/2012 - Company Name
Collegium Pharmaceutical - Mailing Address
400 Highland Corporate Drive Cumberland, RI 02864 - Company Description
Collegium Pharmaceutical is dedicated to the development of proprietary, late stage pharmaceutical products that add market value and clinical benefit to existing drugs. We apply customized pharmaceutical formulations and intellectual property (IP) strategies to drugs that are safe and effective, creating a portfolio of improved pharmaceutical products with a shorter time to market. - Website
http://www.collegiumpharma.com - Transaction Type
Venture Equity - Transaction Amount
$22,500,000 - Transaction Round
Undisclosed - Proceeds Purposes
The round will fund the company for three years. In that time, it expects to file for U.S. approval of a version of oxycodone designed to be harder to tamper with than existing forms of this opioid narcotic. - M&A Terms
- Venture Investor
Longitude Capital Management - Venture Investor
Skyline Ventures - Venture Investor
Boston Millennia Partners - Venture Investor
Frazier Healthcare Ventures
